

The Outlook for Mammalian Cell Culture Capacity


a *BioPharm International* podcast, November 2008

An interview with: **Tom Ransohoff**, vice president and senior consultant, BioProcess Technology Consultants, and **Jim Miller**, president, PharmSource

Interviewed by: **Laura Bush**, editor-in-chief, *BioPharm International*

As seen in the chart below, the authors expect the industry to have 4 million liters of bioreactor capacity by 2013. Of that, 75% will be captive capacity, i.e., owned by biopharmaceutical companies to make their own products.

Thus, only 1 million of the 4 million liters (about 25%) is in the hands of contract manufacturing organizations (CMOs). Only a few CMOs—notably Lonza, Boehringer-Ingelheim, and Celltrion—have invested in large commercial-scale bioreactors. Most of the other 40 or more CMOs are still limited to clinical-scale manufacturing (up to ~2,500 L).



Source: “Cell Culture Manufacturing Capacity: Outlook and Trends Through 2013.” Springfield, VA, and Acton, MA: BioProcess Technology Consultants and PharmSource, 2008.

More information about the report:

www.pharmsource.com/images/pharmsource/PDFs/PS_CellCultBroch120108abstract.pdf

Listen to the podcast at:

www.biopharminternational.com/BioPharmNow